TL;DR: AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (residues 176-191) developed to isolate GH’s fat-metabolizing (lipolytic) activity while avoiding its effects on IGF-1, growth signaling, and glucose. Animal data looked promising, but the largest human obesity trials failed to show significant weight loss.
AOD-9604 (the name is shorthand for “Anti-Obesity Drug 9604”) is one of the more instructive case studies in peptide research: a compound with an elegant scientific rationale, an excellent safety record across roughly 900 trial participants, and yet a clinical development program that was ultimately abandoned because it did not deliver meaningful weight loss in its pivotal trials. Understanding why is far more useful than any marketing claim, and it is the honest way to answer “what is AOD-9604?” This guide is written strictly for research and educational purposes only.
What is AOD-9604?
AOD-9604 is a synthetic hexadecapeptide (16 amino acids) corresponding to the C-terminal region of human growth hormone (hGH), specifically residues 176-191, with a tyrosine added at the N-terminal end to aid stability and synthesis. It was developed by Metabolic Pharmaceuticals Ltd (Melbourne, Australia), building on earlier work by Frank Ng and colleagues who had identified this C-terminal domain as the part of the growth hormone molecule most closely associated with lipolytic (fat-breaking) activity.
The entire scientific premise was separation of function. Full-length growth hormone does many things at once: it stimulates hepatic IGF-1 production, promotes tissue growth, and can impair insulin sensitivity and raise blood glucose with chronic exposure. The 176-191 fragment was designed to retain the fat-metabolism signal while shedding the rest. In laboratory settings today, AOD-9604 is referenced as a research compound, commonly in a 10mg research vial format, and is studied as a tool for probing adipose-tissue lipid metabolism rather than as an approved therapeutic.
How AOD-9604 is Proposed to Work
The mechanistic story for AOD-9604 comes almost entirely from preclinical (animal and in-vitro) work:
- Stimulates lipolysis in fat cells, increasing the breakdown of stored triglycerides into free fatty acids and glycerol
- Inhibits lipogenesis, reducing the conversion of non-fat energy sources into new stored fat
- Does not raise IGF-1 in the way full-length GH does, which was the key selling point of the “separated” fragment
- Does not appear to impair insulin sensitivity in rodent models, unlike chronic intact hGH treatment
A frequently cited detail is the proposed role of the beta-3 adrenergic receptor (beta-3-AR). In knockout-mouse experiments by Heffernan and colleagues, the interaction between the fragment and the beta-3-AR pathway was probed directly, and the literature that followed has interpreted the degree of beta-3-AR dependence in varying ways. What matters for a careful reader is that the mechanism is still incompletely characterized and rests on animal models. It is a plausible, partially supported hypothesis, not settled human physiology.
What the Research Actually Shows
This is where honesty matters most, because the gap between the preclinical promise and the human results is the whole story of AOD-9604.
- 1
Rodent studies (2000-2001)
Obese Zucker rats: >50% less weight gain vs vehicle over ~19 days, no loss of insulin sensitivity.
- 2
Phase II, 12 weeks
Low daily oral dose beat placebo by a few kilograms; safety consistently good.
- 3
Phase IIb, 24 weeks
Several hundred subjects; no statistically significant weight loss vs placebo.
- 4
Program halted (~2007)
Efficacy could not be established, so pharmaceutical development stopped.
- 5
GRAS status (later)
Recognized as safe as a food ingredient - safety only, not a fat-loss approval.
Animal studies were encouraging. In obese Zucker rats, daily oral AOD-9604 reduced body-weight gain by more than 50 percent versus vehicle control over roughly 19 days, and critically did not impair insulin sensitivity on euglycemic clamp testing (Ng et al., 2000). Rodent work by Heffernan and colleagues similarly reported increased fat oxidation and reduced adiposity with chronic treatment. On paper, the “clean lipolysis” hypothesis held up in mice and rats.
Early human trials looked modestly positive. A 12-week Phase II study in obese patients reported that the group receiving a low daily oral dose lost noticeably more weight than placebo (on the order of a few kilograms versus under one kilogram for placebo). Safety and tolerability across the human program were consistently good, with no serious adverse events attributed to the compound (Stier et al., 2013).
The pivotal trial failed. The larger, longer Phase IIb obesity trial, which enrolled several hundred subjects over 24 weeks, did not demonstrate statistically significant weight loss versus placebo. Because efficacy could not be established at the scale and duration required for an obesity drug, Metabolic Pharmaceuticals halted development of AOD-9604 as a pharmaceutical around 2007.
What survived was a food-ingredient status, not a drug approval. On the strength of its safety data, AOD-9604 later received a GRAS (“Generally Recognized As Safe”) determination in the United States for use as a food/nutraceutical ingredient. It is important to read that precisely: GRAS speaks to safety for oral consumption, not to efficacy for fat loss, and it is emphatically not a drug approval for treating obesity.
The bottom line from the literature is a compound that is well-tolerated but whose fat-loss efficacy in humans was never convincingly demonstrated in the trial that mattered most.
AOD-9604 vs GLP-1 Fat-Loss Compounds
A common reason people search for AOD-9604 is to compare it with the modern GLP-1 receptor agonists that now dominate the weight-management conversation. Mechanistically and evidentially, they are not in the same category.
| Feature | AOD-9604 | GLP-1 agonists (e.g. semaglutide) |
|---|---|---|
| Origin | Fragment of human growth hormone (176-191) | Analog of the gut incretin hormone GLP-1 |
| Proposed mechanism | Direct lipolysis / reduced lipogenesis in fat tissue | Appetite suppression, slowed gastric emptying, glycemic control |
| Effect on IGF-1 / growth axis | Designed to avoid it | Not applicable |
| Human efficacy evidence | Pivotal obesity trial failed to show significant weight loss | Large randomized trials show substantial, significant weight loss |
| Regulatory status | GRAS food ingredient; not an approved drug | Approved medicines in many jurisdictions for their indications |
The practical distinction is that GLP-1 compounds such as semaglutide act centrally on appetite and energy intake, with a large randomized-trial evidence base behind their weight outcomes, whereas AOD-9604 was a peripheral, fat-cell-targeted concept whose human weight-loss data did not reach the same bar. They are studied as fundamentally different tools, and conflating them overstates what the AOD-9604 evidence supports. For a sense of how these categories are catalogued in the research-supply market, our price index tracks how the two families are listed and priced.
Forms, Handling, and Research Context
Research-grade AOD-9604 is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use in a laboratory protocol. As with other lyophilized peptides, the diluent is added slowly along the vial wall and the solution is swirled gently rather than shaken, to limit mechanical stress on the peptide.
The chosen vial size determines the final concentration after reconstitution; a 10mg vial is a commonly referenced format in laboratory catalogs. Working out the resulting concentration for a given diluent volume is exactly the kind of calculation our reconstitution calculator is built to handle, which removes a common source of arithmetic error in benchtop record-keeping. None of this constitutes a usage protocol for humans or animals.
Research Considerations
A few recurring variables shape how AOD-9604 appears in the literature:
- Route of administration — much of the original program studied an oral formulation, which is unusual for a peptide and relevant when comparing older oral-dose data to other handling formats
- Trial duration and scale — the encouraging signals came from shorter studies, while the longer, larger 24-week trial is the one that failed, a reminder that duration and statistical power matter
- Species gap — the strongest positive data are in rodents; human efficacy for weight loss was not established
- Safety versus efficacy — a clean safety record (the basis for GRAS status) is a separate question from whether the compound produces meaningful fat loss
These are documented features of the existing record, not instructions for use.
Frequently Asked Questions
Is AOD-9604 approved for weight loss?
No. AOD-9604 is not an approved drug for obesity or any other indication anywhere. Its pivotal human obesity trial failed to show significant weight loss, and development as a pharmaceutical was halted. It later received GRAS food-ingredient status in the US, which addresses safety for consumption, not fat-loss efficacy.
How is AOD-9604 different from full HGH?
AOD-9604 is only the C-terminal fragment (residues 176-191) of human growth hormone, engineered to keep the fat-metabolism signal while avoiding GH’s broader effects. Unlike intact hGH, it is not designed to raise IGF-1 or impair insulin sensitivity, though this “separated function” is best supported in animal models rather than human outcomes.
Does AOD-9604 work like Ozempic or semaglutide?
No, the mechanisms differ entirely. Semaglutide is a GLP-1 receptor agonist that reduces appetite and food intake centrally, with large trials behind its weight results. AOD-9604 was a peripheral, fat-cell-targeted lipolysis concept whose human weight-loss data did not reach comparable significance, so the two are not equivalent.
Is AOD-9604 the same as HGH Fragment 176-191?
They are closely related but not identical. Both derive from the same 176-191 region of growth hormone. AOD-9604 adds a tyrosine residue at the N-terminal end of that fragment, a modification made during its pharmaceutical development. In much of the research literature the terms are used to describe overlapping but distinct synthetic constructs.
Why did AOD-9604 development stop if it was safe?
Safety and efficacy are separate hurdles. AOD-9604 cleared the safety bar comfortably across its human program, but its largest 24-week obesity trial did not demonstrate statistically significant weight loss versus placebo. Without proven efficacy, there was no path to approval as an obesity drug, so the pharmaceutical program was abandoned around 2007.
What does GRAS status mean for AOD-9604?
GRAS (“Generally Recognized As Safe”) is a US regulatory determination that an ingredient is safe for its intended use in food. For AOD-9604 it reflects the compound’s clean tolerability record. It is not a drug approval and makes no claim that the peptide is effective for fat loss or any medical purpose.
References
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology - Endocrinology and Metabolism. 2000;279(3):E501-E507.
- Heffernan M, Summers RJ, Josephs A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. Available at: jofem.org
- More MI, Freitas U, Rutenberg D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism. Available at: jofem.org
- AOD9604 development and clinical overview. Wikipedia. Available at: en.wikipedia.org/wiki/AOD9604
Last updated: July 7, 2026
Disclaimer: This information is for educational and research purposes only. Peptides labeled for research are research chemicals not intended for human consumption, and nothing here constitutes medical advice or a dosing protocol. For handling references, see our AOD-9604 10mg research page.